Please ensure Javascript is enabled for purposes of website accessibility

US Supreme Court Lifts Order That Blocked Trump’s Mass Federal Layoffs

5 hours ago

Trump to Attend Club World Cup Final, FIFA Opens Office in Trump Tower

5 hours ago

Trump Says Pharmaceutical Tariffs Could Reach 200%

5 hours ago

Rescue Teams Find Three More Bodies After Central Texas Floods

5 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Rigoberto Simental Aguilar

6 hours ago

Trump Says He Is Not Happy With Russia’s Putin, Considering Sanctions

6 hours ago

Sean ‘Diddy’ Combs to Be Sentenced on October 3

6 hours ago

Israeli Military Says It Struck Key Hamas Figure in Lebanon’s Tripoli

6 hours ago

Madera County Sheriff Logs 29 Fire-Related Calls on Fourth of July, Most in 5 Years

6 hours ago

Trump Says He May Take Over Governance of Washington, DC

6 hours ago
WHO Study Finds Remdesivir Didn't Help COVID-19 Patients
gvw_ap_news
By Associated Press
Published 5 years ago on
October 16, 2020

Share

GENEVA — A large study led by the World Health Organization suggests that the antiviral drug remdesivir did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries.

The results announced Friday do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival.

The drug has not been approved for COVID-19 in the U.S., but it was authorized for emergency use after the previous study found it shortened recovery time by five days on average. It’s approved for use against COVID-19 in the United Kingdom and Europe, and is among the treatments U.S. President Donald Trump received when he was infected earlier this month.

The WHO study involved more than 11,000 patients in 30 countries. About 2,750 were randomly assigned to get remdesivir. The rest got either the malaria drug hydroxychloroquine, the immune-system booster interferon, the antiviral combo lopinavir-ritonavir, or just usual care. The other drugs have largely been ruled out for COVID-19 by previous studies, but not remdesivir.

“In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)”

The Results Have Not Been Published in a Journal or Reviewed by Independent Scientists

Death rates after 28 days, the need for breathing machines and time in the hospital were relatively similar for those given remdesivir versus usual care.

The results have not been published in a journal or reviewed by independent scientists, but were posted on a site researchers use to share results quickly.

“The big story is the finding that remdesivir produces no meaningful impact on survival,” Martin Landray, an Oxford University professor who led other coronavirus treatment research, said in a statement.

“This is a drug that has to be given by intravenous infusion for five to 10 days,” and costs about $2,550 per treatment course, he said. “COVID affects millions of people and their families around the world. We need scalable, affordable and equitable treatments.”

Dr. Margaret Harris, a WHO spokeswoman, attributed the difference in the conclusions of the two studies to the fact WHO’s was larger.

“It’s just a much higher-powered study,” she said. “It’s quadruple the number of people in all the other studies.”

Results Are Inconsistent With More Rigorous Studies and Have Not Been Fully Reviewed or Published

However, Dr. Andre Kalil, a University of Nebraska infectious disease specialist who helped lead the U.S. remdesivir study, said the WHO one was poorly designed, which makes its conclusions less reliable. Patients and doctors knew what treatment they were using, there was no placebo infusion to help avoid biased reporting of risks or benefits, there was little information about the severity of patients’ symptoms when treatments began and a lot of missing data, he said.

“Poor quality study design cannot be fixed by a large sample size, no matter how large it is,” Kalil wrote in an email.

Furthermore, the WHO study tested 10 days of remdesivir, so some patients may have been hospitalized longer than they needed to be just to finish treatment, making their length of stay look bad in comparison to others getting usual care.

Remdesivir’s maker, Gilead Sciences, said in a statement that the results are inconsistent with more rigorous studies and have not been fully reviewed or published.

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Fresno Woman Sentenced to Prison for DUI Crash That Killed One, Injured Three

DON'T MISS

Union Files Ethics Complaint After College Chancellor’s ‘Goddaughter’ Receives $161K In Contracts

DON'T MISS

Fresno Police Arrest Suspect Tied to 2 Shootings, Firearm Recovered

DON'T MISS

Are Former Measure C Execs Pushing Their Own Ballot Measure?

DON'T MISS

San Luis Obispo’s Madre Fire Near New Cuyama Grows to 80,615 Acres, 35% Contained

DON'T MISS

US Justice Department Scrambles to Defend Its About-Face on Release of Epstein Files

DON'T MISS

US Supreme Court Lifts Order That Blocked Trump’s Mass Federal Layoffs

DON'T MISS

Trump to Attend Club World Cup Final, FIFA Opens Office in Trump Tower

DON'T MISS

Trump Says Pharmaceutical Tariffs Could Reach 200%

DON'T MISS

Rescue Teams Find Three More Bodies After Central Texas Floods

UP NEXT

TSA Set to Let Airport Travelers Keep Their Shoes on, Media Reports Say

UP NEXT

Space Industry Urges Congress Not to Axe System That Prevents Satellite Collisions

UP NEXT

Rescuers Scour Flood Debris in Texas as Hope Fades for Survivors

UP NEXT

US Veterans Affairs Will Cut Nearly 30,000 Jobs, Far Fewer Than Planned

UP NEXT

US Proposes Rules That Could Boost Oil, Gas Output in US West

UP NEXT

Man Dead After Firing at US Border Patrol Station in Texas

UP NEXT

Texas Girls’ Camp Mourning Dozens Dead in Floods as Search Teams Face More Rain

UP NEXT

Death Toll From Texas Floods Reaches 78, Trump Plans Visit

UP NEXT

Death Toll From Texas Floods Reaches 59, Including 21 Children

UP NEXT

Fresno Crash Involving Unlicensed Teen Driver Sends Woman to Hospital

Are Former Measure C Execs Pushing Their Own Ballot Measure?

2 hours ago

San Luis Obispo’s Madre Fire Near New Cuyama Grows to 80,615 Acres, 35% Contained

4 hours ago

US Justice Department Scrambles to Defend Its About-Face on Release of Epstein Files

4 hours ago

US Supreme Court Lifts Order That Blocked Trump’s Mass Federal Layoffs

5 hours ago

Trump to Attend Club World Cup Final, FIFA Opens Office in Trump Tower

5 hours ago

Trump Says Pharmaceutical Tariffs Could Reach 200%

5 hours ago

Rescue Teams Find Three More Bodies After Central Texas Floods

5 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Rigoberto Simental Aguilar

6 hours ago

Trump Says He Is Not Happy With Russia’s Putin, Considering Sanctions

6 hours ago

Sean ‘Diddy’ Combs to Be Sentenced on October 3

6 hours ago

Fresno Woman Sentenced to Prison for DUI Crash That Killed One, Injured Three

A 23-year-old Fresno woman was sentenced Tuesday to more than a decade in state prison for a 2021 drunk driving crash that killed one passen...

32 minutes ago

32 minutes ago

Fresno Woman Sentenced to Prison for DUI Crash That Killed One, Injured Three

1 hour ago

Union Files Ethics Complaint After College Chancellor’s ‘Goddaughter’ Receives $161K In Contracts

Jershawn Worthy was identified as the suspect in two Fresno shootings and is now facing multiple firearm-related charges. (Fresno PD)
1 hour ago

Fresno Police Arrest Suspect Tied to 2 Shootings, Firearm Recovered

2 hours ago

Are Former Measure C Execs Pushing Their Own Ballot Measure?

The Madre Fire near New Cuyama has burned more than 80,615 acres, injured one firefighter, and prompted multiple evacuation orders as crews work to contain the growing wildfire. (CalFire)
4 hours ago

San Luis Obispo’s Madre Fire Near New Cuyama Grows to 80,615 Acres, 35% Contained

U.S. financier Jeffrey Epstein appears in a photograph taken for the New York State Division of Criminal Justice Services' sex offender registry March 28, 2017 and obtained by Reuters July 10, 2019. New York State Division of Criminal Justice Services/Handout via REUTERS/File Photo
4 hours ago

US Justice Department Scrambles to Defend Its About-Face on Release of Epstein Files

A general view of the U.S. Supreme Court building in Washington, U.S., June 1, 2024. (Reuters File)
5 hours ago

US Supreme Court Lifts Order That Blocked Trump’s Mass Federal Layoffs

President Donald Trump holds the key to the FIFA Club World Cup trophy in the Oval Office of the White House in Washington, D.C., U.S., March 7, 2025. (Reuters File)
5 hours ago

Trump to Attend Club World Cup Final, FIFA Opens Office in Trump Tower

Help continue the work that gets you the news that matters most.

Search

Send this to a friend